At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy
In Brief
A clinical study evaluating Emtricitabine, Enfuvirtide, and 3 other interventions for HIV Infections. Completed, enrolled 19 participants across 7 sites in 2 countries.
Detailed Summary
HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
Study Details
Timeline
Interventions
Will be administered as one 200-mg capsule orally daily
Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
Will be administered as one 100-mg capsule orally twice daily
Will be administered as five hard gel capsules orally twice daily
Will be administered as one 300-mg tablet orally daily